DEB-TACE

DEB-TACE vs cTACE in HCC After TIPS

Durvalumab and Tremelimumab in Combination With Y-90 SIRT for Intermediate Stage HCC

ICIs and Anti-VEGF Antibody/TKIs With or Without Interventional Therapy for Advanced HCC

DEB-TACE+RALOX-HAIC vs DEB-TACE for Large HCC

DEB-TACE Prior to Liver Transplantation in the Treatment of HCC

Combined DEB-TACE, Lenvatinib and Pucotenlimab as Conversion Therapy for Unresectable Intrahepatic Cholangiocarcinoma

PVE/PVL Combined With DEB-TACE in the Treatment of Patients With Large and Unresectable Liver Cancer

DEB-TACE Versus DEB-TACE Sequential HAIC for Unresectable BCLC Stage C HCC; A Randomized Controlled Trial

Anti-PD-1 Antibody Plus DEB-TACE for BCLC Stage A/B HCC

Prospective Study to Evaluate Safety of Deb-TACE With 100µ Beads in Patients With Non Resectable HCC

Transarterial Embolization Alone Versus Drug-Eluting Beads Chemoembolization for Hepatocellular Carcinoma

A Study of ONCO-DOX in Locally Advanced Hepatocellular Carcinoma

Efficacy and Safety of TACE on Downstaging Hepatocellular Carcinoma Beyond UCSF Criteria;

Drug-eluting Bead Transarterial Chemoembolisation (DEB-TACE) Versus (VS) Conventional Transarterial Chemoembolisation (cTACE) for Unresectable Hepatocellualr Carcinoma (HCC)

DEB-TACE for Hepatocellular Carcinoma